FOI 6090 Biologics-biosimilars, immunology, anti-TNF, JAK inhibitors, rheumatoid arthritis, rheumatology treatments
Note – dates are response dates
FOI 5341
Date: 30 May 2018
I have a Freedom of Information request regarding Biologics and Biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs for either Rheumatology, Dermatology or Gastroenterology departments.
We do not record in a format to identify the number of patients that are treated with a specific drug or medication.
FOI 5693
Date: 11 December 2018
1) Within your Trust how many patients do you have diagnosed with Rheumatoid Arthritis?
1734; data has been provided for the last 12 months in line with the remaining questions.
2) How many Rheumatoid Arthritis patients have had an IFR [Individual Funding Request] put in for them to have an advanced treatment (i.e. biologic or JAK inhibitor) in the past 12 months?
None
3) How many patients do you have diagnosed with moderate Rheumatoid Arthritis? [moderate is defined within the guidelines as patients with a DAS score of between 3.2 and 5.1]
We do not hold information on DAS Scores
4) How many moderate Rheumatoid Arthritis patients have had an IFR [Individual Funding Request] put in for them to have an advanced treatment (i.e. biologic or JAK inhibitor) in the past 12 months?
None
5) How many moderate Rheumatoid Arthritis patients have been granted an IFR request for an advanced treatment (i.e. biologic or JAK inhibitor) in the past 12 months?
None
6) If possible, please state the number of patients and the name of an advanced treatment (i.e. biologic or JAK inhibitor) provided
N/A
FOI 5712
Date: 4 December 2018
1) I have a Freedom of Information request with regards to the usage of Biologics and Biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs;
We do not record in a format to identify the number of patients that are treated with a specific drug or medication per medical condition
FOI 5731
Date: 8 January 2019
1) I have a Freedom of Information request with regards to the usage of Biologics and Biosimilar prescribing. Could you please provide me with the following USAGE in the last 12 months (latest 12 months possible) of the following drugs;
Please see usage as below –if not listed below, then no usage during this time. So zero value
| Drug Name | Units e.g PFS , tabs |
|---|---|
| ABATACEPT | 150 inj |
| 372 inj | |
| ADALIMUMAB | 10564 inj |
| APREMILAST | 5835 tabs |
| BARICITINIB | 84inj |
| CERTOLIZUMAB PEGOL | 2696 inj |
| DIMETHYL FUMARATE | 14000caps |
| ETANERCEPT | 13324 inj |
| GOLIMUMAB | 665 inj |
| INFLIXIMAB | 4363 inj |
| RITUXIMAB | 2183 vials |
| 178 x50ml | |
| 10 x 10ml | |
| SECUKINUMAB | 452 x 1ml |
| TOCILIZUMAB | 2152 inj |
| TOFACITINIB CITRATE | 1400tabs |
| USTEKINUMAB | 262 inj |
| 42 vials | |
| VEDOLIZUMAB | 192 vials |
FOI 5908
Date: 30 April 2019
1) Does your trust use the following biosimilar biologic therapies, and if possible how many patients are currently being treated?
- Adalimumab [Hyrimoz] Yes
- Adalimumab [Amgevita] No
- Adalimumab [Imraldi] No
- Adalimumab [Hulio] No
- Etanercept [Benepali] Yes
- Etanercept [Erelzi] No
- Infliximab [Inflectra] No
- Infliximab [Remsima] Yes
- Infliximab [Flixabi] No
We do not have the data for number of patients on above.
For questions 2-4; We do not record in a format to identify the number of patients that are treated with a specific drug or medication per medical condition
2) Within your rheumatology department; how many patients in the year 2018 were treated with a biologic or JAK2
- how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]
3) Within your dermatology department;
- how many patients in the year 2018 were treated with a biologic or JAK2
- how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]
4) Within your gastrenterology department;
- how many patients in the year 2018 were treated with a biologic or JAK2
- how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]
5) Does your trust record the DAS score electronically on the patient records?, If so how many are DAS 5+ No/Yes [if Yes number]
Although the DAS is recorded electronically on EPRO, it is in the form of a digital dictation for patient letters, so there would be no way to extract this information.
FOI 6069
Date: 30 May 2019
1) I wonder if you can help with regards to a Freedom of Information request I have for Biologics and Biosimilar prescribing. Could you please provide me with following numbers of patients treated in the last 12 months (latest) 12 months possible) with the following drugs for either Rheumatology, Dermatology and Gastroenterology departments:
Please note - We do not record in a format to identify the number of patients that are treated with a specific drug or medication.